Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

In This Article:

Medicenna Therapeutics Corp.
Medicenna Therapeutics Corp.

MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” BiSKIT (Bifunctional SuperKine for ImmunoTherapy), engineered to deliver an anti-PD1-IL-2 Superkine (anti-PD1-IL-2SK) to the tumor microenvironment (TME), where it is conditionally activated by tumor-associated proteases

MDNA113 treatment achieved complete tumor regression of IL-13Rα2 expressing tumors, highlighting its potential to treat a vast range of malignancies, including immunologically “cold tumors” that annually affect over two million cancer patients worldwide

Internationally recognized academic teams in the UK showed promising pre-clinical results with a long-acting IL-2SK (MDNA11) and anti-PD1-IL-2SK BiSKIT, in mouse models of glioblastoma (GBM) and patient-derived GBM explants

Updated MDNA11 clinical results from the ABILITY-1 study will be presented tomorrow at SITC

TORONTO and HOUSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced that new preclinical data from its BiSKIT (MDNA113) and IL-2 super agonist (MDNA11) programs will be presented today at the 39th Annual Meeting of SITC being held in Houston, Texas. In addition, as announced previously, updated clinical results from the MDNA11 Phase 1/2 ABILITY-1 study will be presented tomorrow, Saturday November 9, 2024 at SITC.

“We are excited to demonstrate our ability to generate novel therapeutics such as MDNA113, to address unmet needs in oncology, by smartly leveraging both our IL-2 and IL-13 Superkine platforms in one molecule,” said Fahar Merchant, Ph.D., President and CEO of Medicenna. “Today’s data demonstrates the effectiveness of MDNA113 to inhibit tumor growth, particularly in IL-13Rα2 positive tumors, and showcase its potential to completely protect and prevent metastasis in an aggressive breast cancer model when administered just once prior to surgery. In a separate presentation, independent work from our academic collaborator in the UK demonstrated the capacity of MDNA11 and anti-PD1-IL-2SK BiSKIT to significantly extend overall survival in an aggressive GBM mouse model and stimulate activity of resident effector immune cells in fresh human GBM explants.”

MDNA113 is based on the Company’s IL-2 and IL-13 Superkine Platforms, the former being used to develop MDNA11, a long-acting IL-2 super agonist, currently being evaluated in the Phase 1/2 ABILITY-1 study for the treatment of advanced and/or metastatic solid tumors.